P882 Effectiveness and safety of voriconazole in primary antifungal prophylaxis for children undergone allogeneic stem cell transplantation

D. Tallon, J.R. Molina, J. Serrano, P. Gomez, A. RodriguezVilla, C. Cerrato, A. Torres

Author address: 

University Hospital Reina Sofi a (Cordoba, ES)

Abstract: 

Introduction: Invasive fungal infection (IFI) incur signifi cant morbidity and mortality among children undergone Allogeneic Stem Cell Transplantation (Allo-SCT) due to neutropenic phase and posterior immunosuppression. We have analyzed in this prospective study our experience in pediatric patients who received voriconazole as primary antifungal prophylaxis undergone Allo-SCT. Methods and patients: A total of 50 children and adolescents 2.5 basal levels in 7 (14%) children. Skin rash (n = 1), pancreatitis (n = 1) and tremor (n = 1) were the others secondary effects observed. All adverse effects were solved once stopped voriconazole. Conclusion: With an overall IFI incidence of 2%, our results suggest that primary antifungal prophylaxis in children undergone Allo-SCT with voriconazole is effective at reducing the incidence of IFI in this type of high risk pediatric patients. Voriconazole is well tolerated despite a high percentage of adverse effects easily solved by drug stopped without life-threatening complications.
2010

abstract No: 

P882

Full conference title: 

Annual Meeting of the EBMT, 36th
    • EBMT 36th (2010)